目的 探讨联合检测CA27-29与CA15-3水平对乳腺浸润性导管癌早期诊断的价值。方法 采用IRMA和CMIA法检测乳腺浸润性导管癌组患者41例、乳腺良性疾病组33例和对照组35名，血清CA27-29与CA15-3水平。结果 乳腺浸润性导管癌组血清CA27-29与CA15-3水平明显高于乳腺良性疾病组和对照组，差异有统计学意义（P<0.05）；CA27-29与CA15-3的阳性率分别为65.9%和56.1%，这两项联合检测阳性率为80.5%，提示CA27-29 异常表达与乳腺浸润性导管癌的发生密切相关。结论 CA27-29可以作为乳腺浸润性导管癌的肿瘤标志物之一，联合检测有助于乳腺浸润性导管癌的早期诊断。

Objective To investigate the value of combined detection of CA27-29 and CA15-3 in early diagnosis of breast infiltrating ductal carcinoma. Methods The study included 41 patients with breast infiltrating ductal carcinoma and 33 patients with benign breast disease. 35 healthy volunteers were served as control group. The serum levels of CA27-29 and CA15-3 in all cases were examined by IRMA and CMIA respectively. Results The serum levels of CA27-29 and CA15-3 in patients with breast infiltrating ductal carcinoma were significantly higher than those in patients with benign breast disease and control group (P<0.05).The positive rates of CA27-29 and CA15-3 in patients with breast infiltrating ductal carcinoma were 65.9% and 56.1%, respectively, while the positive rate of combined detection of CA27-29 and CA153 was 80.5%. It indicated that the abnormal expression of CA27-29 was closely related to the occurrence of breast infiltrating ductal carcinoma. Conclusion The CA27-29 could be served as one of tumor markers in breast infiltrating ductal carcinoma. Combined detection of CA27-29 and CA15-3 might be conducive to early diagnosis of breast infiltrating ductal carcinoma.